Filing Flows › Comparisons › SNY vs NVO
Sanofi vs Novo Nordisk A S: SNY and NVO compared
Sanofi is the larger company: $43.6B of revenue in its latest quarter (FY2025) against $309.1B for Novo Nordisk A S (FY2025). Novo Nordisk A S is growing faster (+6% against +6% a year earlier). Novo Nordisk A S is more profitable, with an operating margin of 41.3% against 14.5%.
Where the money goes: SNY and NVO
Sanofi (SNY) · FY2025
Sanofi, FY2025: revenue $43.6B (+6% year over year), operating margin 14.5%, net earnings $7.8B, operating cash flow $10.8B. The chart follows the revenue to costs, profit and cash.
Novo Nordisk A S (NVO) · FY2025
Novo Nordisk A S, FY2025: revenue $309.1B (+6% year over year), operating margin 41.3%, net earnings $102.4B, operating cash flow $119.1B. The chart follows the revenue to costs, profit and cash.
| Sanofi (SNY) | Novo Nordisk A S (NVO) | |
|---|---|---|
| Latest quarter | FY2025 | FY2025 |
| Revenue | $43.6B | $309.1B |
| Revenue growth, Y/Y | +6% | +6% |
| Gross margin | 77.2% | 81.0% |
| Operating margin | 14.5% | 41.3% |
| Net earnings | $7.8B | $102.4B |
| Net margin | 17.9% | 33.1% |
| Operating cash flow | $10.8B | $119.1B |
| Free cash flow | — | $59.0B |
| Market value | $57.4B | $186.0B |
| P/E | — | 1.8× |
| Analysts’ mean target | $53.48 | $45.63 |
Questions
Which is bigger, Sanofi or Novo Nordisk A S?
Sanofi is the larger company: $43.6B of revenue in its latest quarter (FY2025) against $309.1B for Novo Nordisk A S (FY2025).
Is Sanofi or Novo Nordisk A S growing faster?
Novo Nordisk A S is growing faster (+6% against +6% a year earlier).
Which is more profitable, Sanofi or Novo Nordisk A S?
Novo Nordisk A S is more profitable, with an operating margin of 41.3% against 14.5%.
More: Sanofi earnings · how Sanofi makes money · Novo Nordisk A S earnings · how Novo Nordisk A S makes money
From the companies' latest 10-Q, 10-K or earnings release (20-F filed Feb 17, 2026; 20-F filed Feb 4, 2026). Fiscal quarters can end on different dates. Not investment advice.